Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated MelanomaGeorgina V. Long, John M. Kirkwood, Bijoyesh Mookerjee et al.|New England Journal of Medicine|2017Cited by 1.5k
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600–Mutant Stage III MelanomaAxel Hauschild, Georgina V. Long, Reinhard Dummer et al.|Journal of Clinical Oncology|2018Cited by 255
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trialDirk Schadendorf, Georgina V. Long, Axel Hauschild et al.|The Lancet Oncology|2019Cited by 56
Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III <i>BRAF</i>-mutant melanoma.Dirk Schadendorf, Georgina V. Long, Axel Hauschild et al.|Journal of Clinical Oncology|2018Cited by 10
25LBA Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) + vemurafenib (VEM) in the phase 3 coBRIM studyGrant A. McArthur, A. Ribas, James Larkin et al.|European Journal of Cancer|2015Cited by 10